Company overview
ProteomEdge develops multiplex panels of isotope-labeled protein standards for absolute protein quantification using mass spectrometry. Their products support biomarker research and translational applications in blood-based proteomics for pharma and life sciences. The company offers DiscoveryEdge 600 and plans additional targeted panels and expanded discovery products in early 2026.
ProteomEdge is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, Diagnostics & Testing partner serving United States & Americas. Core focus areas include protein quantification, mass spectrometry standards, isotope labeled proteins, blood proteomics, biomarker research.
Industry categories: Life Science Reagents, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://proteomedge.com
- Categories
- Life Science Reagents, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- protein quantification, mass spectrometry standards, isotope labeled proteins, blood proteomics, biomarker research
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What products does ProteomEdge offer for protein quantification?
- ProteomEdge provides multiplex panels of isotope-labeled protein standards, including DiscoveryEdge 600, for absolute quantification via mass spectrometry in biomarker research and blood proteomics.
- What are ProteomEdge's key capabilities in mass spectrometry?
- They develop proprietary MS-based analysis platforms delivering state-of-the-art accuracy for precise, scalable measurement of clinically relevant proteins.
- Where is ProteomEdge located and what is their background?
- ProteomEdge is based in Stockholm, Sweden, founded in 2023 by researchers from the Human Protein Atlas and SciLifeLab.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
